Pontocerebellar hypoplasia type 2D in two Acadian families: functional RNA characterization of the recurrent SEPSECS c.388+3A>G variant
15 affiliations
- 1Vitalité Health Network, Moncton, NB, Canada
- 2University of Sherbrooke, Sherbrooke, QC, Canada
- 3University of Moncton, Department of Chemistry and Biochemistry, Moncton, NB, Canada
- 4Atlantic Cancer Research Institute, Moncton, NB, Canada
- 5Centre de Formation Médicale du Nouveau-Brunswick, Moncton, NB, Canada
- 6IWK Health Centre, Division of Medical Genetics, Halifax, NS, Canada
- 7Dalhousie University, Department of Pediatrics, Halifax, NS, Canada
- 8Stan Cassidy Centre for Rehabilitation, Fredericton, NB, Canada
- 9Fulgent Genetics, El Monte, CA, United States
- 10Program in Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada
- 11The Centre for Computational Medicine, SickKids Research Institute, Toronto, ON, Canada
- 12Division of Clinical & Metabolic Genetics, Hospital for Sick Children, Toronto, ON, Canada
- 13Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
- 14Program in Developmental and Stem Cell Biology, SickKids Research Institute, Toronto, ON, Canada
- 15Department of Pediatrics, University of Toronto, Toronto, ON, Canada
Abstract
Background: Pontocerebellar hypoplasia type 2D (PCH2D, OMIM #613811) is an ultra-rare autosomal recessive neurodevelopmental disorder caused by biallelic pathogenic variants in SEPSECS, which encodes a key enzyme required for selenoprotein biosynthesis. An extensive literature review conducted for this report identified approximately 34 genetically confirmed patients from 26 families with SEPSECS-related disease across the published literature, underscoring the extreme rarity of PCH2D. Intronic splice-altering variants with functional RNA confirmation remain poorly characterized, and no population-specific founder variant has been established for SEPSECS-related PCH2D.
Methods: We performed detailed clinical, molecular, and transcriptomic analyses in three affected individuals from two unrelated Acadian families originating from the Canadian Maritime provinces. All individuals underwent exome sequencing, followed by RNA-based analyses of patient-derived samples to assess the functional impact of the recurrent intronic SEPSECS variant.
Results: Exome sequencing identified the same homozygous intronic SEPSECS variant, c.388 + 3A>G, in all three affected individuals. The variant was initially classified as a variant of uncertain significance in patients 1 and 2 and as likely pathogenic in patient 3 by different diagnostic laboratories. RNA analysis demonstrated aberrant splicing with exon 3 skipping, generating an out-of-frame transcript consistent with a loss-of-function mechanism. Residual normally spliced transcript was also detected in blood-derived RNA, consistent with a partial or “leaky” splice defect at the transcript level. These findings supported pathogenic reclassification and established a molecular diagnosis of PCH2D. Clinically, the patients presented with early-onset lower-extremity spasticity, gait abnormalities, nystagmus, and mild neurodevelopmental delay, but had an attenuated clinical course compared to classical severe PCH2D.
Conclusion: This case series expands the molecular and clinical spectrum of SEPSECS-related PCH2D by providing functional RNA evidence for a recurrent non-canonical intronic splice variant and documenting an attenuated infantile-onset presentation. The recurrence of c.388 + 3A>G in individuals of Acadian ancestry raises the possibility of a candidate Acadian founder allele. These findings underscore the importance of transcript-level analyses for interpreting intronic variants and improving diagnosis in ultra-rare neurodevelopmental disorders.
Related
- Comprehensive in silico analysis reveals candidate regulatory mechanisms underlying selective cerebellar vulnerability in pontocerebellar hypoplasia
- Charcot-Marie-Tooth disease with intermediate motor nerve conduction velocities: Characterization of 14 C×32 mutations in 35 families
- Ethylene Biosynthesis Dynamics and Genome-Wide Characterization of the ACS and ACO Gene Families During Fruit Development in 'Kuerle Xiangli' (Pyrus sinkiangensis Yu).
- Sequence and epigenetic characterization of chromosome 21 centromeres in a family with recurrent Trisomy 21
- Synergistic Variants in C-terminal Binding Protein 1 and Alkaline Phosphatase Lead to Mandibular Hypoplasia Through Impaired Wnt Signaling: An Oligogenic Model
BibTeX
@article{bouhamdani2026pontocerebellar,
title = {{Pontocerebellar hypoplasia type 2D in two Acadian families: functional RNA characterization of the recurrent SEPSECS c.388+3A>G variant}},
author = {Nadia Bouhamdani and Raphael Fournier and Sarah Dyack and Kayla Roddick and Elina Nikkola and ZhenBin Chen and Neta Pipko and Yijing Liang and Ashish R. Deshwar and Gregory Costain and Inas Al-Younis and Mouna Ben Amor},
journal = {Frontiers in Genetics},
year = {2026},
month = oct,
doi = {10.3389/fgene.2026.1954385},
url = {https://doi.org/10.3389/fgene.2026.1954385},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pontocerebellar hypoplasia type 2D in two Acadian families: functional RNA characterization of the recurrent SEPSECS c.388+3A>G variant
AU - Nadia Bouhamdani
AU - Raphael Fournier
AU - Sarah Dyack
AU - Kayla Roddick
AU - Elina Nikkola
AU - ZhenBin Chen
AU - Neta Pipko
AU - Yijing Liang
AU - Ashish R. Deshwar
AU - Gregory Costain
AU - Inas Al-Younis
AU - Mouna Ben Amor
PY - 2026
DA - 2026/10/30
JO - Frontiers in Genetics
DO - 10.3389/fgene.2026.1954385
UR - https://doi.org/10.3389/fgene.2026.1954385
AB - Background: Pontocerebellar hypoplasia type 2D (PCH2D, OMIM #613811) is an ultra-rare autosomal recessive neurodevelopmental disorder caused by biallelic pathogenic variants in SEPSECS, which encodes a key enzyme required for selenoprotein biosynthesis. An extensive literature review conducted for this report identified approximately 34 genetically confirmed patients from 26 families with SEPSECS-related disease across the published literature, underscoring the extreme rarity of PCH2D. Intronic splice-altering variants with functional RNA confirmation remain poorly characterized, and no population-specific founder variant has been established for SEPSECS-related PCH2D. Methods: We performed detailed clinical, molecular, and transcriptomic analyses in three affected individuals from two unrelated Acadian families originating from the Canadian Maritime provinces. All individuals underwent exome sequencing, followed by RNA-based analyses of patient-derived samples to assess the functional impact of the recurrent intronic SEPSECS variant. Results: Exome sequencing identified the same homozygous intronic SEPSECS variant, c.388 + 3A>G, in all three affected individuals. The variant was initially classified as a variant of uncertain significance in patients 1 and 2 and as likely pathogenic in patient 3 by different diagnostic laboratories. RNA analysis demonstrated aberrant splicing with exon 3 skipping, generating an out-of-frame transcript consistent with a loss-of-function mechanism. Residual normally spliced transcript was also detected in blood-derived RNA, consistent with a partial or “leaky” splice defect at the transcript level. These findings supported pathogenic reclassification and established a molecular diagnosis of PCH2D. Clinically, the patients presented with early-onset lower-extremity spasticity, gait abnormalities, nystagmus, and mild neurodevelopmental delay, but had an attenuated clinical course compared to classical severe PCH2D. Conclusion: This case series expands the molecular and clinical spectrum of SEPSECS-related PCH2D by providing functional RNA evidence for a recurrent non-canonical intronic splice variant and documenting an attenuated infantile-onset presentation. The recurrence of c.388 + 3A>G in individuals of Acadian ancestry raises the possibility of a candidate Acadian founder allele. These findings underscore the importance of transcript-level analyses for interpreting intronic variants and improving diagnosis in ultra-rare neurodevelopmental disorders.
SN - 1664-8021
ER -